文献速递MDS 与骨髓增殖性肿瘤白血病

DHODH抑制剂PTC299与去甲基化药物协同治疗MDS

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2021-01-01

本研究探讨新型DHODH抑制剂PTC299对骨髓增生异常综合征(MDS)的作用。PTC299抑制MDS细胞系增殖(外源尿苷可逆转),但单药抑制生长和诱导分化效果不及AML细胞;与地西他滨等去甲基化药物联用呈协同抑制生长,并在原代MDS样本中证实。机制涉及S期阻滞、凋亡及增强地西他滨掺入DNA,MYC为PTC299主要靶点之一。

要点

  • PTC299单药抑制MDS细胞增殖,外源尿苷可逆转该效应
  • PTC299与地西他滨在MDS细胞及原代样本中协同抑制生长
  • PTC299通过抑制嘧啶合成增强地西他滨掺入DNA,MYC为其靶点之一

核心结论

  • DHODH抑制剂PTC299抑制MDS细胞生长,并与地西他滨协同作用,可能成为MDS新的治疗选择。

研究设计与样本

  • 研究为体外细胞系与原代MDS样本实验,并在MDS细胞系异种移植小鼠模型中评估PTC299单药及联合地西他滨的疗效。

主要发现

  • PTC299抑制MDS细胞系增殖,外源尿苷可逆转;对MDS细胞抑制生长和诱导分化效果不及AML细胞。
  • PTC299与地西他滨等去甲基化药物协同抑制MDS细胞生长,原代MDS样本中亦证实该协同效应。
  • PTC299单药延长MDS细胞系异种移植小鼠生存,联合地西他滨作用更强。
  • 机制上PTC299诱导S期阻滞继而凋亡,并通过抑制嘧啶生成增强地西他滨掺入DNA。
  • RNA-seq显示PTC299处理后MYC靶基因集明显下调,转染MYC可大幅减弱PTC299的生长抑制作用。

临床怎么用

  • 提示DHODH抑制剂联合去甲基化药物可能作为MDS的潜在治疗策略,尚需进一步临床研究验证。

局限性

  • 证据主要来自MDS细胞系、原代样本及小鼠异种移植模型,尚缺乏临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dihydroorotate dehydrogenase (DHODH) catalyzes a rate-limiting step in de novo pyrimidine nucleotide synthesis. DHODH inhibition has recently been recognized as a potential new approach for treating acute myeloid leukemia (AML) by inducing differentiation. We investigated the efficacy of PTC299, a novel DHODH inhibitor, for myelodysplastic syndrome (MDS). PTC299 inhibited the proliferation of MDS cell lines, and this was rescued by exogenous uridine, which bypasses de novo pyrimidine synthesis. In contrast to AML cells, PTC299 was inefficient at inhibiting growth and inducing the differentiation of MDS cells, but synergized with hypomethylating agents, such as decitabine, to inhibit the growth of MDS cells. This synergistic effect was confirmed in primary MDS samples. As a single agent, PTC299 prolonged the survival of mice in xenograft models using MDS cell lines, and was more potent in combination with decitabine. Mechanistically, a treatment with PTC299 induced intra-S-phase arrest followed by apoptotic cell death. Of interest, PTC299 enhanced the incorporation of decitabine, an analog of cytidine, into DNA by inhibiting pyrimidine production, thereby enhancing the cytotoxic effects of decitabine. RNA-seq data revealed the marked downregulation of MYC target gene sets with PTC299 exposure. Transfection of MDS cell lines with MYC largely attenuated the growth inhibitory effects of PTC299, suggesting MYC as one of the major targets of PTC299. Our results indicate that the DHODH inhibitor PTC299 suppresses the growth of MDS cells and acts in a synergistic manner with decitabine. This combination therapy may be a new therapeutic option for the treatment of MDS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kayamori K, Nagai Y, Zhong C, et al. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes. Blood Adv. 2021. PMID: 33496740. doi:10.1182/bloodadvances.2020001461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。